Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

hma later this month."

2013 Business Highlights EYLEA® (aflibercept) Injection for Intravitreal Injection

  • EYLEA is currently approved in the United States for the treatment of neovascular age-related macular degeneration (wet AMD) and macular edema following central retinal vein occlusion (CRVO).  In the first quarter of 2013, net sales were $314 million, compared to $124 million in the first quarter of 2012, and $276 million in the fourth quarter of 2012.
  • The Company and Bayer HealthCare collaborate on the global development and commercialization of EYLEA outside the United States, and share profits and losses from commercialization of EYLEA outside the United States except for Japan, where the Company receives a royalty on sales.  Regeneron maintains exclusive rights to EYLEA in the United States and is entitled to all profits from any such sales.
  • Bayer HealthCare commenced sales of EYLEA for the treatment of wet AMD in the fourth quarter of 2012 following receipt of regulatory approvals in the European Union, Japan, Australia, and other regions.  In the first quarter of 2013, Bayer HealthCare recorded net sales of EYLEA outside of the United States of $65 million, compared to $19 million in the fourth quarter of 2012.  Our share of profits (including royalties on sales in Japan) for EYLEA was $19 million, and after repaying $13 million in development expenses, we recognized $6 million in net profit from EYLEA sales outside the United States in the quarter.
  • Launches in additional countries are anticipated to continue throughout 2013 as regulatory and pricing approvals for EYLEA for the treatment of wet AMD are achieved.
  • Applications for marketing authorization for EYLEA for the treatment of macular edema following CRVO are also pending in Europe, Japan, and other regions.
  • Regeneron and Bayer HealthCare are conducting Phase 3 trials, VISTA-DME and VIVID-DME,
    '/>"/>

  • SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
    2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
    3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
    4. Regeneron Announces March 2012 Investor Conference Presentations
    5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
    6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
    7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
    8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
    9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
    10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
    11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... 18, 2014 Leatherwood Plastics has ... material, to stay competitive in the semiconductor, clean ... materials ultimately impact product quality and productivity, according ... , Established in 1980 in Lewisville, TX, ... fabricators have left the business. Much of Leatherwood’s ...
    (Date:9/18/2014)... 18, 2014  MEI Pharma, Inc. (Nasdaq: MEIP ... novel therapies for cancer, announced today that Daniel P. ... at BioCentury,s NewsMakers in the Biotech Industry conference ... from the Millennium Broadway Hotel & Conference Center in ... presentation can be accessed at www.meipharma.com . A replay ...
    (Date:9/18/2014)... Oncothyreon Inc. (NASDAQ: ONTY ) today announced ... offerings of 10,000,000 shares of its Common Stock at ... for expected gross proceeds of $20 million and 10,000 ... a price to the public of $2,000.00 per share, ... of Series A Convertible Preferred Stock is non-voting and ...
    (Date:9/18/2014)... 2014   Sigma-Aldrich Corporation (Nasdaq: ... into a new gene editing partnership with the ... Under the partnership, Sigma-Aldrich will provide the Vector ... and dedicated gene editing bioinformaticians. The ... at the U-M Medical School. One initiative already ...
    Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
    ... Mich., Sept. 26 MichBio, the,association for Michigan,s life ... held October 16 in East Lansing. Michigan State,University has ... event on,its campus. Career Day is intended to introduce ... educational and career opportunities in,the life sciences. It takes ...
    ... HILL, N.C., Sept. 26 The landscape of ... the advent of,transparency guidelines. Half of global publications ... publications leaders foresee a shift,to medical groups to ... by Best Practices, LLC. In a benchmarking ...
    ... Mylan Laboratories Inc.,(NYSE: MYL ) will host ... acquisition. Pending the closing, the investor day will take ... Robert J. Coury, Mylan,s,Vice Chairman and Chief Executive Officer, ... Generics and Matrix Laboratories will,provide a detailed financial and ...
    Cached Biology Technology:MichBio Announces Student Career Day at Michigan State University 2Industry Executives Finding Value in Shift of Scientific Publications 2
    (Date:9/18/2014)... ultimate form of camouflage: you don,t just blend in, ... not as uncommon as you might think. Kathryn Feller, ... that the larval life stages of many marine species ... anatomy that most creatures cannot make transparent. Feller explains ... each individual eye unit with an opaque pigment to ...
    (Date:9/17/2014)... instrumental in the creation of the Santa Ana Wildfire ... fire threat potential of the powerful, hot, dry Santa ... inferno. The index was introduced Sept. 17 by the ... Diego Gas and Electric. , The index includes four ... be used to help fire agencies and other emergency ...
    (Date:9/17/2014)... SAN DIEGO, Calif. (Sept. 17, 2014) A rare genetic ... autism, according to a recent joint investigation by researchers ... California, San Diego. In addition to suggesting better treatment ... offers more clues into the genetic underpinnings of autism., ... to the National Institutes of Health. It occurs in ...
    Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2A link between Jacobsen syndrome and autism 2
    ... and Environmental Engineering suggests how aquatic plants in rivers and ... large areas of ocean coastal waters. This work, ... of Fluid Mechanics (JFM), describes the physics of water flow ... to environmental engineering. This new understanding can be used to ...
    ... and Budget evaluates R&D programs at the U.S. Environmental ... asks about many aspects of their research, including its ... and an "ineffective" rating can have serious adverse consequences ... meeting OMB,s requirements to measure and demonstrate efficiency, EPA ...
    ... US national grids has enabled UCL (University College London) scientists ... a key protein used by the lethal virus. The method ... action could one day be used to tailor personal ... their drugs. The study, published online today in the ...
    Cached Biology News:River plants may play major role in health of ocean coastal waters 2Virtual human in HIV drug simulation 2
    Rabbit polyclonal to SUR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide Entrez Gene ID: 6833 Swiss Protein ID: Q09428...
    ... ARG. Vasopressin The antibody blocks ... are found in the paraventricular and ... throughout the hypothalmus in rat brain ... Immunogen: Arginine Vasopression ...
    Pronase Reagent...
    Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
    Biology Products: